ArticleCancer research and treatment2022

The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma.

Yen-Hsiang Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.